Abstract:Background and objectives: Opioid maintenance treatment (OMT), with methadone or buprenorphine, is a key approach for managing opioid use disorder (OUD) during pregnancy. Despite buprenorphine's superior short-term outcomes, its long-term effects remain understudied. This study aims to evaluate the effects of prenatal OMT exposure on the incidence of childhood neurodevelopmental disorders (NDDs) considering timing effect. Methods: A retrospective cohort study using Rhode Island Medicaid data linked to vital statistics from 2008 to 2018 was conducted. The study included pregnancies having live birth from 2008 to 2016 with continuous Medicaid insurance and OUD diagnosis within 3 months preceding conception until delivery. At least one buprenorphine dispensing or a claim of methadone was required for exposure definition. Exposure was evaluated during early (0-90 days) or late (>90 days) gestation, or at any pregnancy phase. NDDs, including autism, attention-deficit/hyperactivity disorder (ADHD), learning disabilities, speech/language disorders, developmental coordination disorder, intellectual disability, and behavioral disorders, were identified using validated algorithms. Applying Cox proportional-hazard models with propensity score overlap weighting, adjusted hazard ratios (aHR) were calculated, mitigating potential confounders. Children were followed up from birth until NDD diagnosis, disenrollment, or study end. Results: Of 416 mother-child dyads with OUD, 40% used methadone and 20% had buprenorphine exposure during pregnancy. NDDs were observed in 36% of children with early methadone exposure compared to 17% in the early buprenorphine exposed group (aHR: 2.75; 95% confidence interval [CI]: 1.42-5.35). Further comparison to late buprenorphine exposure, late methadone exposure was associated with higher NDD risk (aHR: 2.05; 95% CI: 1.09-3.86). Compared to unexposed group, children exposed to methadone during early and late periods showed higher NDD incidences (aHR: 2.33; 95% CI: 1.51-3.60 and aHR: 2.42; 95% CI: 1.54-3.80, respectively). Discussion: The study suggests that buprenorphine is a good treatment option for OUD during pregnancy due to minimal long-term neurodevelopmental impacts on children. However, further extensive research is necessary to rule-out potential confounding.

Buprenorphine and methadone differentially alter early brain development in human cortical organoids

Methadone Interrupts Neural Growth and Function in Human Cortical Organoids.

Methadone Suppresses Neuronal Function and Maturation in Human Cortical Organoids

Differential Effects of Prenatal Buprenorphine and Methadone on Postnatal Growth and Gene Expression in the Nucleus Accumbens

Molecular and Long-Term Behavioral Consequences of Neonatal Opioid Exposure and Withdrawal in Mice.

The effects of buprenorphine and morphine during pregnancy: Impact of exposure length on maternal brain, behavior, and offspring neurodevelopment

Neurodevelopmental outcomes in children prenatally exposed to opioid maintenance treatment: A population-based study

Shared and Divergent Transcriptomic Regulation in Nucleus Accumbens D1 and D2 Medium Spiny Neurons by Cocaine and Morphine

Prenatal buprenorphine exposure decreases neurogenesis in rats

Gestational buprenorphine exposure: Effects on pregnancy, development, neonatal opioid withdrawal syndrome, and behavior in a translational rodent model

Methadone directly impairs central nervous system cells in vitro

Maternal exposure to buprenorphine, but not methadone, during pregnancy reduces social play behavior across two generations of offspring

Effects of prenatal exposure to methadone or buprenorphine and maternal separation on anxiety-like behavior in rats

Verbal and nonverbal memory in school-aged children born to opioid-dependent mothers

Assessing Neonatal Opioid Withdrawal Syndrome Severity as a Function of Maternal Buprenorphine Dose and Umbilical Cord Tissue Concentrations

481 Interactions between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome

Neurobehavioral outcomes of infants exposed to buprenorphine-naloxone compared with naltrexone during pregnancy

Abnormal Morphology and Synaptogenic Signaling in Astrocytes Following Prenatal Opioid Exposure

Prenatal heroin exposure alters brain morphology and connectivity in adolescent mice

DNA methylation patterns in umbilical cord blood from infants of methadone maintained opioid dependent mothers